Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

50.54
-1.0700-2.07%
Volume:96.48K
Turnover:4.87M
Market Cap:1.75B
PE:-12.90
High:51.81
Open:51.61
Low:49.87
Close:51.61
Loading ...

CFO Jean M. Franchi Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
19 Jun

Disc Medicine Price Target Maintained With a $118.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jun

Promising Potential of Disc Medicine’s Bitopertin Drives Buy Rating

TIPRANKS
·
17 Jun

Disc Medicine’s Promising Clinical Pipeline and Strong Financial Position Justify Buy Rating

TIPRANKS
·
16 Jun

Disc Medicine Inc. Unveils Presentation on Innovative Approaches to Hematologic Disorders Targeting Iron and Heme Metabolism

Reuters
·
16 Jun

Disc Medicine Inc. Unveils EHA 2025 Corporate Presentation Highlighting Investigational Agents and Clinical Program Updates

Reuters
·
16 Jun

Disc Medicine Inc. i Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Disc Medicine Announces Positive Clinical Data and Plans for NDA Submission at EHA 2025 for Bitopertin in Erythropoietic Protoporphyria

Reuters
·
12 Jun

Disc Medicine Price Target Announced at $89.00/Share by Raymond James

Dow Jones
·
12 Jun

Disc Medicine Inc : Raymond James Resumes Coverage With Strong Buy Rating; Target Price $89

THOMSON REUTERS
·
11 Jun

Chief Medical Officer William Jacob Savage Reports Disposal of Common Shares of Disc Medicine Inc

Reuters
·
10 Jun

Press Release: CHAMPION IRON REPORTS ITS FY2025 FOURTH QUARTER RESULTS AND DECLARES DIVIDEND

Dow Jones
·
29 May

Chief Medical Officer William Jacob Savage Reports Disposal of Common Shares in Disc Medicine Inc

Reuters
·
23 May

Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), Medtronic (MDT) and Disc Medicine (IRON)

TIPRANKS
·
22 May

Disc Medicine Inc. to Present Hematology Portfolio Data at European Hematology Association Congress

Reuters
·
14 May

Disc Medicine Inc. to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Reuters
·
13 May

Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025

Dow Jones
·
08 May

Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP

TIPRANKS
·
08 May

Disc Medicine’s Strong Financial Health and Promising Clinical Pipeline Justify Buy Rating

TIPRANKS
·
08 May

Disc Medicine Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May